BlackRock Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

BlackRock Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.23M	Buy	12,238 +511	+4%	+$87.1K	﹤0.01%	1460
2016 Q3	$1.92M	Buy	11,727 +269	+2%	+$40.8K	﹤0.01%	1490
2016 Q2	$1.64M	Sell	11,458 -103,754	-90%	-$14.8M	﹤0.01%	1531
2016 Q1	$15.8M	Buy	115,212 +868	+0.8%	+$114K	0.02%	610
2015 Q4	$15.9M	Buy	114,344 +5,085	+5%	+$705K	0.02%	626
2015 Q3	$14.7M	Buy	109,259 +57,534	+111%	+$8.28M	0.02%	631
2015 Q2	$7.79M	Buy	51,725 +48,717	+1,620%	+$6.97M	0.01%	842
2015 Q1	$407K	Hold	3,008	–	–	﹤0.01%	2240
2014 Q4	$363K	Hold	3,008	–	–	﹤0.01%	2235
2014 Q3	$341K	Hold	3,008	–	–	﹤0.01%	2266
2014 Q2	$360K	Hold	3,008	–	–	﹤0.01%	2251
2014 Q1	$385K	Buy	3,008 +101	+3%	+$12.9K	﹤0.01%	2233
2013 Q4	$359K	Buy	2,907 +207	+8%	+$25.2K	﹤0.01%	2284
2013 Q3	$317K	Sell	2,700 -80	-3%	-$9.44K	﹤0.01%	2247
2013 Q2	$312K	Buy	+2,780	New	+$326K	﹤0.01%	2171

Other funds holding BIO

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

BlackRock Advisors's BIO Position: Q4 2016 in Review

BlackRock Advisors increased its Bio-Rad Laboratories Class A (BIO) stake by 4.4% in Q4 2016, buying an estimated $87.1K and bringing the position to 12,238 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

BlackRock Advisors first reported a position in BIO in Q2 2013 and has held it in 15 quarters since. The position peaked at $15.9M in Q4 2015. 261 funds tracked by Wall St. Rank hold BIO as of Q4 2016.

BlackRock Advisors held 12,238 shares of Bio-Rad Laboratories Class A worth $2.23M as of Q4 2016.
BlackRock Advisors bought 511 Bio-Rad Laboratories Class A shares in Q4 2016, an estimated $87.1K.
Bio-Rad Laboratories Class A made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1460 holding.
BlackRock Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Bio-Rad Laboratories Class A position peaked at $15.9M in Q4 2015.
261 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.